Premium Nahrungsergänzungsmittel | artgerecht

Fisher Syndrome: Symptoms, Causes and Treatment

Fisher syndrome is a rare neurological condition characterised by eye muscle paralysis, coordination problems, and absent tendon reflexes.

Regular tips about health Regular tips about health

Things worth knowing about "Fisher Syndrome"

Fisher syndrome is a rare neurological condition characterised by eye muscle paralysis, coordination problems, and absent tendon reflexes.

What is Fisher Syndrome?

Fisher syndrome (also known as Miller Fisher syndrome) is a rare variant of Guillain-Barré syndrome – a group of conditions in which the immune system mistakenly attacks the peripheral nervous system. It was first described in 1956 by Canadian neurologist C. Miller Fisher. The condition is defined by a classic triad of three hallmark symptoms: paralysis of the eye muscles (ophthalmoplegia), impaired coordination when walking (ataxia), and the absence of tendon reflexes (areflexia).

Causes

Fisher syndrome is an autoimmune disorder in which the immune system produces antibodies against the body's own nerve structures. In more than 90% of cases, blood tests reveal anti-GQ1b antibodies, which target a glycolipid (GQ1b) found in particularly high concentrations in the nerve sheaths of the cranial nerves that control eye movement.

The condition is often preceded by an infectious illness that triggers the immune response. Common triggers include:

Infection with Campylobacter jejuni (the most frequent bacterial trigger)
Infection with Haemophilus influenzae
Viral infections, such as influenza, Epstein-Barr virus, or cytomegalovirus
In rare cases: vaccinations or surgical procedures

Symptoms

The classic symptom triad of Fisher syndrome includes:

Ophthalmoplegia: Paralysis or weakness of the external eye muscles, causing double vision (diplopia) and restricted eye movement. Drooping of the eyelid (ptosis) may also occur.
Ataxia: Coordination problems that mainly affect walking and standing, typically without significant muscle weakness.
Areflexia: Complete absence of tendon reflexes, such as the knee-jerk reflex.

Additional symptoms may include:

Tingling or numbness in the hands and feet
Facial muscle weakness (facial palsy)
Difficulty swallowing or speaking
In rare cases: breathing difficulties (if the condition progresses to full Guillain-Barré syndrome)

Diagnosis

Diagnosis of Fisher syndrome is primarily clinical, based on the characteristic triad, supported by the following investigations:

Blood test: Detection of anti-GQ1b antibodies (positive in over 90% of patients)
Lumbar puncture (spinal tap): Cerebrospinal fluid often shows elevated protein levels with a normal cell count – a pattern known as albuminocytological dissociation
Nerve conduction studies (electroneurography): To assess nerve damage
Brain MRI: To rule out other causes such as brainstem lesions or stroke

Treatment

Fisher syndrome generally carries a favourable prognosis and often resolves spontaneously within weeks to months. Treatment is guided by the severity of symptoms:

Watchful waiting: In mild cases, careful monitoring without active treatment may be sufficient.
Intravenous immunoglobulins (IVIG): Antibody preparations that modulate the misdirected immune response and can shorten the course of illness.
Plasmapheresis (plasma exchange): A procedure in which the blood plasma is filtered to remove disease-causing antibodies.
Physiotherapy: To support rehabilitation and improve coordination and balance.
Ophthalmological care: For persistent eye muscle problems, specialist follow-up may be beneficial.

Corticosteroids have not been shown to be effective in Fisher syndrome and are generally not recommended.

Prognosis and Outlook

The vast majority of patients make a full recovery within three to six months. Permanent neurological deficits are uncommon. In a small number of cases, Fisher syndrome may progress to a full Guillain-Barré syndrome, which may require intensive medical care.

References

Fisher, C.M. (1956): An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). New England Journal of Medicine, 255(2), 57–65.
Willison, H.J., Jacobs, B.C., van Doorn, P.A. (2016): Guillain-Barré syndrome. The Lancet, 388(10045), 717–727.
Ito, M. et al. (2011): Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. Journal of Neurology, 255(5), 674–682.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.